Big Pharma's Executive Brain Drain Benefits Biotech
This article was originally published in Start Up
Executive Summary
Big Pharma has provided its executives with unrivaled stability, opportunity, and financial rewards, but swelling numbers are fleeing corporate offices for tiny biotechs. A blip in good times for biotech or a sea change for the industry?
You may also be interested in...
Biotech IPOs: High Tide
Since 2013, investors have rallied around biotech IPOs like never before. START-UP looks at the current window and the implications of investor enthusiasm for newly public companies.
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Patheon Tightens The Supply Chain To Transform Pharma Outsource Manufacturing
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.